17 Aug
Extracted from Optimal Clinical Trials EDM – 17th August 2020. Published with permission.
After 102 days of being COVID-19 free, New Zealand has a new outbreak. As at 9am Saturday 15th August 2020 we have 56 active cases, 17 of which are due to the new outbreak and the rest are imported cases. All are in managed isolation. Since the beginning of the pandemic New Zealand has had 1609 total confirmed and probable cases with 1531 recovered and 22 deaths1.
The New Zealand government has responded swiftly and as of Wednesday 12 August 12 noon Auckland has been moved to Alert level 3. The rest of New Zealand is at alert level 2. This will stay in place until 11:59pm Wednesday 26 August. The Government aims to keep the economy going while prioritising peoples health.
Whilst this is regrettable we have been planning for this and have swung our plans into action. We continue to prioritise safety but also to continue operations and keep your studies moving.
Optimal Clinical Trials is considered an essential business by the New Zealand Government and so can continue to operate at all alert levels.
Below is a table detailing operations at each alert level. Our team will be in touch with you to keep things moving for existing studies and studies in start up. We will continue to communicate with you.
Please stay safe and we look forward to continuing to work with you.
Dr Barney Montgomery
Managing Director
Optimal Clinical Trials
1source: https://covid19.govt.nz
Further Information
Clinical Trial Landscape
Clinical Trials is considered an essential business in New Zealand and trial activity continues across all alert levels. Optimal and many other sites are set up to conduct trials with in clinic visits as well as virtual trials.
Ethics & Regulatory approval
New Zealand’s online application and approval system is fully operational, with approval times within 35 days. An expedited process has been implemented to approve COVID-19 research much more quickly.
Monitoring & Start up activities
Monitoring and start up activities continue – with New Zealand offering both on site remote support.
Local laboratories & imaging facilities
Private laboratories and radiology providers continue to support clinical trial activities.
Transportation & logistics
New Zealand borders remain open to freight, ensuring that IP supplies reach sites, and central laboratory specimens are delivered to overseas laboratories. Local couriers and transportation services remain operational at ground level, ensuring timely delivery of temperature sensitive supplies, dry ice etc.
Recruitment & participant visits
Under all alert levels essential safety visits continue.
Brief information about New Zealand and Optimal Clinical Trials
We are keeping clinical trials running
Please contact us for more information about conducting you research in New Zealand. Or, click here to get your free guide: "Successful Clinical Trials: How to accelerate your clinical program; get your first patient in quickly and meet your clinical trial milestones"
New Zealand wants to help
Dr Barney Montgomery
Managing Director
barney@optimalclinicaltrials.com || +64 21 951 954
Dr Liz Smaill
General Manager
liz@optimalclinicaltrials.com || +64 21 538 865
Optimal Clinical Trials
P O Box 47476, Ponsonby, Auckland 1144
2nd Floor, 97 Grafton Rd, Grafton, Auckland 1010, New Zealand
P +64 (9) 303 4987 | F +64 (9) 379 6582
www.optimalclinicaltrials.com
About Optimal Clinical Trials
Optimal Clinical Trials: We are people on a mission – to reduce suffering and help people around the world gain a better quality of life through research.
We are a private, independently owned clinical research site in Auckland (population 1.5m), New Zealand’s largest city. We have grown rapidly and won multiple awards.
We specialise in conducting commercial phase 1b to 3 non-oncology trials. We have a wide range of therapeutic areas with our expert investigators and specialists.
We regularly work with the world’s largest pharmaceutical companies, CRO’s and many biotech’s. We are known for our speed, quality and responsiveness to client’s needs.
The safety of our patients, staff and partners is our primary concern and we continue to maintain our extensive safety measures to minimise possible transmission.
Other News
March 2024 (1)
February 2024 (1)
December 2023 (1)
November 2023 (1)
October 2023 (1)
September 2023 (2)
August 2023 (1)
July 2023 (1)
June 2023 (2)
May 2023 (3)
April 2023 (1)
March 2023 (2)
The Go-to region for clinical trials (1)
HiRO – our global advantage, tailored solutions and key partnerships (1) (1)
HiRO – an emerging full-service global CRO (1)
HiRO – Top CRO in APAC 2022 (1) (1)
November 2022 (1)
October 2022 (1)
September 2022 (1)
August 2022 (1)
July 2022 (1)
June 2022 (1)
May 2022 (1)
April 2022 (1)
March 2022 (1)
January 2022 (1)
December 2021 (1)
November 2021 (1)
October 2021 (2)
September 2021 (2)
August 2021 (3)
July 2021 (3)
June 2021 (2)
May 2021 (1)
April 2021 (2)
March 2021 (1)
February 2021 (1)
December 2020 (5)
November 2020 (1)
October 2020 (5)
September 2020 (1)
August 2020 (2)
May 2020 (5)
January 2024 (0)